Literature DB >> 10229159

An international view of hydroxyethyl starches.

J Treib1, J F Baron, M T Grauer, R G Strauss.   

Abstract

Hydroxyethyl starch (HES) is one of the most frequently used plasma substitutes. A variety of different HES solutions exist worldwide, which differ greatly in their pharmacological properties. HES is classified according to its manufactured or in vitro molecular weight (MW) into high MW (450-480 kDa), medium MW (200 kDa), and low MW (70 kDa) starch preparations. However, this is not sufficient, because as HES is metabolized in vivo, its MW changes, and it is the in vivo MW which is responsible for the therapeutic and adverse effects of each HES. The rate of metabolization depends mainly on the degree of hydroxyethyl substitution (ranging from 0.4 to 0.7), and the C2/C6 ratio of hydroxyethylation. A high degree of substitution and a high C2/C6 ratio lead to a slow metabolization of HES, resulting in a large in vivo MW. Slowly degradable high MW HES 450/0.7 and medium MW HES 200/0.62 have a high in vivo MW and are eliminated slowly via the kidneys. As a result, these starches have a relatively long-lasting volume effect. When infusing higher volumes (>1500 ml) are infused, large molecules accumulate in the plasma. This can result in bleeding complications due to decreased factor VIII/von Willebrand factor, platelet function defects, incorporation into fibrin clots, and an unfavorable effect on rheological parameters. Rapidly degradable medium MW HES 200/0.5 or low MW HES 70/0.5 are quickly split in vivo into smaller, more favorable molecule sizes, resulting in faster renal elimination, shorter volume effect, and fewer adverse effects on coagulation and rheological parameters. For historical and marketing reasons, only slowly degradable, high MW HES (480/0.7) is available in the United States. In Europe, a large variety of HES solutions are available, dominated by medium MW, easily degradable HES (200/0.5). Because of increasing international competition and the availability of newly developed starches, it is important to be aware of the pharmacological properties of HES and the advantages and disadvantages of the individual preparations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229159     DOI: 10.1007/s001340050833

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  41 in total

1.  Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution.

Authors:  Christoph Eisenbach; Alexander H Schönfeld; Norbert Vogt; Moritz N Wente; Jens Encke; Wolfgang Stremmel; Eike Martin; Ernst Pfenninger; Markus A Weigand
Journal:  Intensive Care Med       Date:  2007-06-07       Impact factor: 17.440

2.  Topographical correlations of lateral medullary infarction with caloric- and vestibular-evoked myogenic potential results.

Authors:  Chih-Lung Tseng; Yi-Ho Young
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-06-27       Impact factor: 2.503

Review 3.  Hydroxyethyl starch for cardiovascular surgery: a systematic review of randomized controlled trials.

Authors:  Xue-Yin Shi; Zui Zou; Xing-Ying He; Hai-Tao Xu; Hong-Bin Yuan; Hu Liu
Journal:  Eur J Clin Pharmacol       Date:  2011-03-02       Impact factor: 2.953

4.  Chloroquine-Modified Hydroxyethyl Starch as a Polymeric Drug for Cancer Therapy.

Authors:  Richard Sleightholm; Bin Yang; Fei Yu; Ying Xie; David Oupický
Journal:  Biomacromolecules       Date:  2017-07-14       Impact factor: 6.988

5.  Narrative reviews from a fraudulent author: reasons to retract.

Authors:  Christiane S Hartog; Anders Perner
Journal:  Intensive Care Med       Date:  2019-02-14       Impact factor: 17.440

6.  HES 130/0.4 impairs haemostasis and stimulates pro-inflammatory blood platelet function.

Authors:  Maik Sossdorf; Sascha Marx; Barbara Schaarschmidt; Gordon P Otto; Ralf A Claus; Konrad Reinhart; Christiane S Hartog; Wolfgang Lösche
Journal:  Crit Care       Date:  2009-12-22       Impact factor: 9.097

7.  Comparison of coagulation factors and blood loss between O and non-O blood types following hydroxyethyl starch infusion.

Authors:  Soo Joo Choi; Hyun Joo Ahn; Jae Ik Lee
Journal:  Korean J Anesthesiol       Date:  2010-04-28

8.  Update on transfusion solutions during surgery: review of hydroxyethyl starches 130/0.4.

Authors:  Ornella Piazza; Giuliana Scarpati; Rosalba Tufano
Journal:  Int J Gen Med       Date:  2010-10-05

9.  Preferred plasma volume expanders for critically ill patients: results of an international survey.

Authors:  Frédérique Schortgen; Nicolas Deye; Laurent Brochard
Journal:  Intensive Care Med       Date:  2004-09-28       Impact factor: 17.440

10.  Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients.

Authors:  Franziska Schabinski; Janaina Oishi; Fabio Tuche; Alain Luy; Yasser Sakr; Donald Bredle; Christiane Hartog; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.